Selegiline in Outpatient Treatment for Cocaine Dependence - 1

National Institute on Drug Abuse (NIDA)

Overview

The purpose of this study is to evaluate the efficacy and clinical safety of selegiline in the treatment of cocaine dependence and to assess neurotoxicity (Magnetic Resonance Imaging, MRI) post-hoc as a possible variable for future stratification in clinical trials.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Cocaine-Related Disorders

Interventions

SelegilineDRUG

Eligibility

Sex: ALLMin age: 21 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: M/F ages 21-50. Meets DSM-IV criteria for cocaine. Agreeable to conditions of study and signed informed consent. Exclusion Criteria: Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.

Locations (1)

Friends Research Institute

Los Angeles, California, United States

Outcomes

Primary Outcomes

Urine toxicology for cocaine

Self reports of cocaine and other drug use and craving

Evidence of change in neurotoxicity based on choreoathetoid movement assessments

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.